The synthesis and in vitro activities of a series of succinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the alpha-carbon of the P1 residue.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2007.02.046DOI Listing

Publication Analysis

Top Keywords

identification novel
4
novel class
4
class succinyl-nitrile-based
4
succinyl-nitrile-based cathepsin
4
cathepsin inhibitors
4
inhibitors synthesis
4
synthesis vitro
4
vitro activities
4
activities series
4
series succinyl-nitrile-based
4

Similar Publications

Discovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.

J Am Chem Soc

December 2024

Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States.

Discovery of cancer immunogenic chemotherapeutics represents an emerging, highly promising direction for cancer treatment that uses a chemical drug to achieve the efficacy of both chemotherapy and immunotherapy. Herein, we report a high-throughput screening platform and the subsequent discovery of a new class of cancer immunogenic chemotherapeutic leads. Our platform integrates informatics-based activity metabolomics for the rapid identification of microbial natural products with both novel structures and potent activities.

View Article and Find Full Text PDF

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.

Malays J Pathol

December 2024

National Institutes of Health, Institute for Medical Research, Cancer Research Centre, Haematology Unit, 40170 Shah Alam, Selangor, Malaysia.

Introduction: The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.

View Article and Find Full Text PDF

Breast cancer (BRCA) is one of the pivotal causes of female death worldwide. And the morbidity and mortality of breast cancer have increased rapidly. Immune checkpoints are important to maintain immune tolerance and are regarded as important therapeutic targets.

View Article and Find Full Text PDF

Past research has demonstrated the association between social engagement and the maintenance of cognitive abilities. However, inconsistent definitions of social engagement have posed challenges to systematically investigate this association. This paper addresses the role of social relationships in cognitive functioning among older adults, focusing on the real-life communication indicator-length of own speech-as a measure of social activity.

View Article and Find Full Text PDF

Innovative modified-net architecture: enhanced segmentation of deep vein thrombosis.

Sci Rep

December 2024

School of Electronics Engineering, Vellore Institute of Technology, Vellore, 632014, Tamilnadu, India.

A new era for diagnosing and treating Deep Vein Thrombosis (DVT) relies on precise segmentation from medical images. Our research introduces a novel algorithm, the Modified-Net architecture, which integrates a broad spectrum of architectural components tailored to detect the intricate patterns and variances in DVT imaging data. Our work integrates advanced components such as dilated convolutions for larger receptive fields, spatial pyramid pooling for context, residual and inception blocks for multiscale feature extraction, and attention mechanisms for highlighting key features.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!